Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Recruiting now · Early Phase 1
Conditions studied: Lymphedema
In brief
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
Key facts
- Study ID
- NCT07012642
- Run by
- Advanced Reconstructive Surgery Alliance
- People needed
- 110
- Starts
- 2025-04-09
- Expected to finish
- 2027-04-09
- Last updated by the study team
- 2025-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% BMI => 23 Oncology clearance if there is a cancer history
You may not qualify if…
- Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.
Where it is running
- River Center — Red Bank, New Jersey, United States (enrolling)
- 260 Old Hook Rd Suite 304 — Westwood, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.